首頁 > 市場調查報告書 > 醫療設備

體外診斷生技設備

北美傳染病分子診斷市場預測至 2030 年 - 區域分析 - 按類型（照護端檢測和實驗室檢測）、最終用戶、應用、疾病類型、感染類型

市場調查報告書

商品編碼

1494288

北美傳染病分子診斷市場預測至 2030 年 - 區域分析 - 按類型（照護端檢測和實驗室檢測）、最終用戶、應用、疾病類型、感染類型

North America Molecular Diagnostics for Infectious Disease Market Forecast to 2030 - Regional Analysis - by Type (Point-of-Care Testing and Laboratory Testing), End User, Application, Disease Type, Infection Type

出版日期: 2024年03月14日 | 出版商:

The Insight Partners | 英文 108 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

2022年北美傳染病分子診斷市值為33.4515億美元，預計2030年將達到84.197億美元；預計2022年至2030年複合年成長率為12.2%。

個人化醫療中的傳染病分子診斷推動了北美傳染病分子診斷市場

隨著高通量技術的進步，基因組研究變得更加方便和具有成本效益。分子診斷在臨床實驗室中變得越來越不可或缺，因為這些試劑盒和測試可以提供快速的檢測結果，而傳統測試則需要在少數情況下在實驗室條件下培養微生物。根據每位患者獨特的基因組成、生活方式和環境，使用精準醫學為每位患者量身定做醫療治療和介入措施。分子診斷在這種方法中發揮重要作用，因為它能夠識別影響患者治療相關決策的特定生物標記、基因突變和基因表現模式。藥物開發越來越依賴分子診斷。各種分子影像技術用於篩檢、檢測、診斷、治療和評估異質性，以製定進展計劃、檢查分子特徵和監測患者結果。個人化醫療通常旨在詢問患者的基因組資訊，例如藥物代謝多態性有助於指導藥物選擇和劑量。在傳染病中，個人化醫學概念可用於快速識別致病微生物，確定其抗菌藥物抗藥性，並根據結果確定適當的抗菌治療，以便對患者進行適當的管理。傳染病的即時檢測需要醫療當局的認可、新技術和通訊平台的開發以及報銷政策，以便最大數量的患者能夠從挽救生命和節省時間的程序中受益。將這些技術引入臨床實踐將能夠識別每個患者的分子標靶，並有助於追蹤疾病的分子進展。

因此，隨著技術的不斷發展，傳染病分子診斷市場似乎有著光明的前景。

北美傳染病分子診斷市場概述

墨西哥結核病（TB）盛行率的不斷上升以及結核病診斷和治療意識的提高正在推動傳染病分子診斷市場的成長。根據 StopTB Partnership Organization 的數據，結核病的人數從 2019 年的 30,000 人增加到 2020 年的 31,000 人。這些項目包括墨西哥索諾拉州和下加利福尼亞州檢測藥物敏感和抗藥性結核病病例的兩個項目。這兩個計畫的共同目標是建立州和國家疾病控制計畫的能力，以識別高風險族群並對該族群進行快速結核病檢測。這些針對群眾進行結核病篩檢的措施正在提高墨西哥民眾的意識。此外，製藥業的廣泛發展、醫療保健基礎設施的發展以及對診斷測試產品的需求不斷增加，都促進了墨西哥傳染病分子診斷市場的成長。 2021 年 2 月，世界衛生組織 (WHO) 宣佈在兒童、青少年和成人的結核病和抗藥性診斷方面取得重大進展。宣布的三類新用於檢測結核病的新技術如下：

用於診斷結核病並檢測利福平和異煙肼抗藥性變異體的中等複雜度自動化核酸擴增測試 (NAAT)
用於檢測異煙肼和二線抗結核藥物抗藥性的低複雜性自動化 NAAT
基於高複雜性雜交的 NAAT，用於檢測吡嗪醯胺抗藥性。

北美傳染病分子診斷市場收入及 2030 年預測（百萬美元）

北美傳染病分子診斷市場區隔

北美傳染病分子診斷市場根據類型、最終用戶、應用、疾病類型、感染類型和國家進行細分。

根據類型，北美傳染病分子診斷市場分為即時檢測和實驗室檢測。到2022年，實驗室檢測領域將佔據北美傳染病分子診斷市場更大的市場佔有率。

北美傳染病分子診斷市場依最終用戶分類，分為現場檢測和實驗室檢測。現場護理測試進一步分為人體測試和獸醫測試。同樣，實驗室測試進一步分為人體測試和獸醫測試。到 2022 年，人體檢測領域（按現場檢測）將佔據更大的北美傳染病分子診斷市場。疾病市場佔有率。

根據應用，北美傳染病分子診斷市場分為即時檢測和實驗室檢測。即時檢測進一步細分為單一病原體的檢測、兩種或多種病原體的檢測、新出現的新型感染的評估、生物威脅製劑和疾病相關生物標記的監測和早期檢測以及抗菌素抗藥性分析。同樣，實驗室檢測進一步分為患者分層、藥物治療方案選擇、毒性避免、治療監測和疾病易感性檢測。到 2022 年，透過現場檢測進行單一病原體檢測，佔據北美最大的傳染病分子診斷市場。佔有率。

根據疾病類型，北美傳染病分子診斷市場分為即時檢測和實驗室檢測。照護端檢測進一步細分為敗血症（例如泌尿生殖系統/肺/傷口）、假體關節感染、心內膜炎、性病、單核細胞增多症、A 型鏈球菌等。同樣，實驗室檢測進一步分為敗血症、人工關節感染、心內膜炎、性傳染病、披衣菌、胃腸道感染、結核、H1N1病毒等。以床邊檢測計算，STD 細分市場將在2022 年佔據北美最大的傳染病分子診斷市場。佔有率。

根據感染類型，北美傳染病分子診斷市場分為即時檢測和實驗室檢測。即時檢測進一步細分為細菌、病毒、真菌等。同樣，實驗室檢測進一步分為細菌、病毒、真菌等。根據即時檢測，細菌細分市場將在 2022 年佔據北美最大的傳染病分子診斷市場。年。

依國家分類，北美傳染病分子診斷市場分為美國、加拿大和墨西哥。 2022年，美國將主導北美傳染病分子診斷市場。

Abbott Laboratories、bioMerieux SA、Bruker Corp、Danaher Corp、DiaSorin SpA、F. Hoffmann-La Roche Ltd、Hologic Inc、Siemens Healthineers AG 和 Thermo Fisher Scientific Inc 是北美傳染病分子診斷領域的一些領先公司疾病市場。

Genome research has become more convenient and cost-effective with progress in high-throughput techniques. Molecular diagnostics is becoming increasingly indispensable in clinical laboratories as these kits and tests provide rapid detection results as opposed to conventional tests, which involve culturing microbes in laboratory conditions in a few cases. Medical treatments and interventions are tailored to each patient using precision medicine based on their unique genetic makeup, lifestyle, and environment. Molecular diagnostics plays an important role in this approach, as it enables the identification of specific biomarkers, genetic mutations, and gene expression patterns that impact decision-making related to the treatment of patients. Drug development has become increasingly dependent on molecular diagnostics. Various molecular imaging techniques are used in screening, detecting, diagnosing, treating, and assessing heterogeneity to make progression plans, examine molecular characteristics, and monitor patient outcomes. Personalized medicine generally aims to interrogate the genomic information of a patient, e.g., drug metabolism polymorphisms help guide drug choice and dosage. In infectious diseases, personalized medicine concepts can be used to rapidly identify disease-causing microorganisms, determine their antimicrobial resistance profiles, and ascertain an appropriate antimicrobial treatment for the proper management of the patient based on the results. Point-of-care testing for infectious diseases requires the acceptance of medical authorities, development of new technology and communication platforms, and reimbursement policies so that the greatest number of patients can benefit from lifesaving and time-saving procedures. Introducing these techniques into clinical practice would enable the identification of molecular targets in each patient, along with facilitating the tracking of the molecular progression of diseases.

Thus, with ever-evolving technology, the market for molecular diagnostics for infectious diseases seems to have a bright future.

North America Molecular Diagnostics for Infectious Disease Market Overview

The increasing prevalence of tuberculosis (TB) and rise in awareness of diagnosis and treatment for TB in Mexico is fueling the growth of the molecular diagnosis for infectious diseases market. According to StopTB Partnership Organization, the number of people suffering from TB rose from 30,000 in 2019 to 31,000 in 2020. The growing focus of Centers for Disease Control and Prevention (CDC) has established several international laboratory projects in Mexico. These projects include two projects for the detection of drug-sensitive and drug-resistant TB cases in Sonora and Baja California, Mexico. The common goal of these two projects is to build capacity for state and national disease control program to identify the group at risk and conduct rapid TB tests on that group. These initiatives for screening the masses for TB are creating awareness in the Mexican population. In addition, the extensively growing pharmaceuticals industry, developing healthcare infrastructure, and elevating demand for diagnostic testing products bolster the molecular diagnostics for infectious diseases market growth in Mexico. In February 2021, the World Health Organization (WHO) announced significant advancements in the diagnosis of TB and drug resistance in children, adolescents, and adults. The three new classes of technologies announced for testing TB were as follows:

Moderate-complexity automated Nucleic Acid Amplification Tests (NAATs) for the diagnosis of TB and detection of variants resistant to rifampicin and isoniazid
Low-complexity automated NAATs for detection of resistance to isoniazid and second-line anti-TB agents
High-complexity hybridization-based NAATs for the detection of resistance to pyrazinamide.

North America Molecular Diagnostics for Infectious Disease Market Revenue and Forecast to 2030 (US$ Million)

North America Molecular Diagnostics for Infectious Disease Market Segmentation

The North America molecular diagnostics for infectious disease market is segmented based on type, end user, application, disease type, infection type, and country.

Based on type, the North America molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. The laboratory testing segment held a larger North America molecular diagnostics market for infectious disease market share in 2022.

The North America molecular diagnostics for infectious disease market, by end user, is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further bifurcated into human testing and vet testing. Similarly, laboratory testing is further bifurcated into human testing and vet testing. The human testing segment, by point-of-care testing, held a larger North America molecular diagnostics market for infectious disease market share in 2022. Additionally, the human testing segment, by laboratory testing, held a larger North America molecular diagnostics market for infectious disease market share in 2022.

Based on application, the North America molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further segmented into detection of single pathogen, detection of two or more pathogens, evaluation of emerging novel infections, surveillance and early detection of biothreat agents and diseases-related biomarker, and antimicrobial resistance profiling. Similarly, laboratory testing is further categorized into patient stratification, drug regimen selection, toxicity avoidance, therapeutic monitoring, and detection of predisposition to disease. The detection of a single pathogen segment, by point-of-care testing, held the largest North America molecular diagnostics for infectious disease market share in 2022. Additionally, the drug regimen selection segment, by laboratory testing, held the largest North America molecular diagnostics for infectious disease market share in 2022.

Based on disease type, the North America molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further segmented into sepsis (e.g. urogenital/lung/wound), prosthetic joint infection, endocarditis, STDs, mononucleosis, group A streptococcus, and others. Similarly, laboratory testing is further categorized into sepsis, prosthetic joint infection, endocarditis, STDs, chlamydia, gastrointestinal infection, tuberculosis, H1N1 virus, and others. The STDs segment, by point-of-care testing, held the largest North America molecular diagnostics for infectious disease market share in 2022. Additionally, the STDs segment, by laboratory testing, held the largest North America molecular diagnostics for infectious disease market share in 2022.

Based on infection type, the North America molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. The point-of-care testing is further segmented into bacteria, viral, fungi, and others. Similarly, laboratory testing is further categorized into bacteria, viral, fungi, and others. The bacteria segment, by point-of-care testing, held the largest North America molecular diagnostics for infectious disease market share in 2022. Additionally, the bacteria segment, by laboratory testing, held the largest North America molecular diagnostics for infectious disease market share in 2022.

Based on country, the North America molecular diagnostics for infectious disease market is categorized into the US, Canada, and Mexico. The US dominated the North America molecular diagnostics for infectious disease market in 2022.

Abbott Laboratories, bioMerieux SA, Bruker Corp, Danaher Corp, DiaSorin SpA, F. Hoffmann-La Roche Ltd, Hologic Inc, Siemens Healthineers AG, and Thermo Fisher Scientific Inc are some of the leading companies operating in the North America molecular diagnostics for infectious disease market.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights
2.2 North America Molecular Diagnostic for Infectious Diseases Market, by Country, Market attractiveness

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. North America Molecular Diagnostic for Infectious Diseases Market - Key Industry Dynamics

4.1 Market Drivers:
- 4.1.1 Surging Prevalence of Infectious Disease Globally
- 4.1.2 Rising Application of Molecular Diagnostics in Veterinary Infectious Diseases
4.2 Market Restraints
- 4.2.1 Limitations Associated with Molecular Testing
4.3 Market Opportunities
- 4.3.1 Advancements in Molecular Diagnostics Technologies
4.4 Future Trends
- 4.4.1 Molecular Diagnostics for Infectious Diseases in Personalized Medicine
4.5 Impact Analysis:

5. Molecular Diagnostic for Infectious Diseases Market - North America Market Analysis

5.1 North America Molecular Diagnostic for Infectious Diseases Market Revenue (US$ Mn), 2022 - 2030

6. North America Molecular Diagnostic for Infectious Diseases Market - Revenue and Forecast to 2030 - by Type

6.1 Overview
6.2 North America Molecular Diagnostic for Infectious Diseases Market Revenue Share, by Type, 2022 & 2030 (%)
6.3 Point-of-Care Testing
- 6.3.1 Overview
- 6.3.2 Point-of-Care Testing: North America Molecular Diagnostic for Infectious Diseases Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Laboratory Testing
- 6.4.1 Overview
- 6.4.2 Laboratory Testing: North America Molecular Diagnostic for Infectious Diseases Market - Revenue and Forecast to 2030 (US$ Million)

7. North America Molecular Diagnostic for Infectious Diseases Market - Revenue and Forecast to 2030 - by End User

7.1 Overview
7.2 North America Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing and Laboratory Testing by End User, 2022 & 2030 (%)
- 7.2.1 North America Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020-2030 (US$ Million)
- 7.2.2 North America Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020-2030 (US$ Million)

8. North America Molecular Diagnostic for Infectious Diseases Market - Revenue and Forecast to 2030 - by Application

8.1 Overview
8.2 Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Application, 2022 & 2030 (%)
8.3 Point-of-Care Testing
- 8.3.1 Overview
- 8.3.2 North America Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020-2030 (US$ Million)
8.4 Laboratory Testing
- 8.4.1 Overview
- 8.4.2 North America: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020-2030 (US$ Million)

9. North America Molecular Diagnostic for Infectious Diseases Market - Revenue and Forecast to 2030 - by Disease Type

9.1 Overview
9.2 North America Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Disease Type, 2022 & 2030 (%)
9.3 Point-of-Care Testing
- 9.3.1 Overview
- 9.3.2 North America Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020-2030 (US$ Million)
  - 9.3.2.1 North America Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020-2030 (US$ Million)
9.4 Laboratory Testing
- 9.4.1 Overview
- 9.4.2 North America Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020-2030 (US$ Million)
  - 9.4.2.1 North America Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020-2030 (US$ Million)

10. North America Molecular Diagnostic for Infectious Diseases Market - Revenue and Forecast to 2030 - by Infection Type

10.1 Overview
10.2 North America Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Infection Type, 2022 & 2030 (%)
10.3 Point-of-Care Testing
- 10.3.1 Overview
- 10.3.2 North America Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020-2030 (US$ Million)
10.4 Laboratory Testing
- 10.4.1 Overview
- 10.4.2 North America Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020-2030 (US$ Million)

11. North America Molecular Diagnostic for Infectious Diseases Market - Country Analysis

11.1 North America Molecular Diagnostic for Infectious Diseases Market, Revenue and Forecast To 2030
- 11.1.1 Overview
- 11.1.2 North America Molecular Diagnostic for Infectious Diseases Market, by Country
  - 11.1.2.1 US
    - 11.1.2.1.1 US Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
    - 11.1.2.1.2 US: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020-2030 (US$ Million)
    - 11.1.2.1.3 US: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020-2030 (US$ Million)
    - 11.1.2.1.4 US: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020-2030 (US$ Million)
    - 11.1.2.1.5 US: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020-2030 (US$ Million)
    - 11.1.2.1.6 US: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020-2030 (US$ Million)
    - 11.1.2.1.7 US: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020-2030 (US$ Million)
    - 11.1.2.1.7.1 US: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020-2030 (US$ Million)
    - 11.1.2.1.8 US: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020-2030 (US$ Million)
    - 11.1.2.1.8.1 US: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020-2030 (US$ Million)
    - 11.1.2.1.9 US: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020-2030 (US$ Million)
    - 11.1.2.1.10 US: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020-2030 (US$ Million)
  - 11.1.2.2 Canada
    - 11.1.2.2.1 Canada Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
    - 11.1.2.2.2 Canada: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020-2030 (US$ Million)
    - 11.1.2.2.3 Canada: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020-2030 (US$ Million)
    - 11.1.2.2.4 Canada: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020-2030 (US$ Million)
    - 11.1.2.2.5 Canada: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020-2030 (US$ Million)
    - 11.1.2.2.6 Canada: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020-2030 (US$ Million)
    - 11.1.2.2.7 Canada: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020-2030 (US$ Million)
    - 11.1.2.2.7.1 Canada: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020-2030 (US$ Million)
    - 11.1.2.2.8 Canada: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020-2030 (US$ Million)
    - 11.1.2.2.8.1 Canada: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020-2030 (US$ Million)
    - 11.1.2.2.9 Canada: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020-2030 (US$ Million)
    - 11.1.2.2.10 Canada: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020-2030 (US$ Million)
  - 11.1.2.3 Mexico
    - 11.1.2.3.1 Mexico Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
    - 11.1.2.3.2 Mexico: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020-2030 (US$ Million)
    - 11.1.2.3.3 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020-2030 (US$ Million)
    - 11.1.2.3.4 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020-2030 (US$ Million)
    - 11.1.2.3.5 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020-2030 (US$ Million)
    - 11.1.2.3.6 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020-2030 (US$ Million)
    - 11.1.2.3.7 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020-2030 (US$ Million)
    - 11.1.2.3.7.1 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020-2030 (US$ Million)
    - 11.1.2.3.8 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020-2030 (US$ Million)
    - 11.1.2.3.8.1 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020-2030 (US$ Million)
    - 11.1.2.3.9 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020-2030 (US$ Million)
    - 11.1.2.3.10 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020-2030 (US$ Million)

12. Industry Landscape

12.1 Overview
12.2 Growth Strategies Done by the Companies in the Market, (%)
12.3 Organic Developments
- 12.3.1 Overview
12.4 Inorganic Developments
- 12.4.1 Overview

13. Company Profiles

13.1 F. Hoffmann-La Roche Ltd
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Abbott Laboratories
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Thermo Fisher Scientific Inc
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 bioMerieux SA
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Danaher Corp
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Hologic Inc
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Siemens Healthineers AG
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Bruker Corp
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 DiaSorin SpA
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments

14. Appendix

14.1 About Us
14.2 Glossary of Terms

簡介目錄圖表

List Of Tables

Table 1. North America Molecular Diagnostic for Infectious Diseases Market Segmentation
Table 2. North America Molecular Diagnostic for Infectious Diseases Market, for Point of Care Testing by End User - Revenue and Forecast to 2030 (US$ Million)
Table 3. North America Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User - Revenue and Forecast to 2030 (US$ Million)
Table 4. North America Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application - Revenue and Forecast to 2030 (US$ Million)
Table 5. North America Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application - Revenue and Forecast to 2030 (US$ Million)
Table 6. North America Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type - Revenue and Forecast to 2030 (US$ Million)
Table 7. North America Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing - Revenue and Forecast to 2030 (US$ Million)
Table 8. North America Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type - Revenue and Forecast to 2030 (US$ Million)
Table 9. North America Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing - Revenue and Forecast to 2030 (US$ Million)
Table 10. North America Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type - Revenue and Forecast to 2030 (US$ Million)
Table 11. North America Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type - Revenue and Forecast to 2030 (US$ Million)
Table 12. US Molecular Diagnostic for Infectious Diseases Market, by Type - Revenue and Forecast to 2030 (US$ Million)
Table 13. US Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User - Revenue and Forecast to 2030 (US$ Million)
Table 14. US Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User - Revenue and Forecast to 2030 (US$ Million)
Table 15. US Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application - Revenue and Forecast to 2030 (US$ Million)
Table 16. US Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application - Revenue and Forecast to 2030 (US$ Million)
Table 17. US Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type - Revenue and Forecast to 2030 (US$ Million)
Table 18. US Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing - Revenue and Forecast to 2030 (US$ Million)
Table 19. US Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type - Revenue and Forecast to 2030 (US$ Million)
Table 20. US Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing - Revenue and Forecast to 2030 (US$ Million)
Table 21. US Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type - Revenue and Forecast to 2030 (US$ Million)
Table 22. US Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type - Revenue and Forecast to 2030 (US$ Million)
Table 23. Canada Molecular Diagnostic for Infectious Diseases Market, by Type - Revenue and Forecast to 2030 (US$ Million)
Table 24. Canada Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User - Revenue and Forecast to 2030 (US$ Million)
Table 25. Canada Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User - Revenue and Forecast to 2030 (US$ Million)
Table 26. Canada Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application - Revenue and Forecast to 2030 (US$ Million)
Table 27. Canada Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application - Revenue and Forecast to 2030 (US$ Million)
Table 28. Canada Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type - Revenue and Forecast to 2030 (US$ Million)
Table 29. Canada Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing - Revenue and Forecast to 2030 (US$ Million)
Table 30. Canada Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type - Revenue and Forecast to 2030 (US$ Million)
Table 31. Canada Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing - Revenue and Forecast to 2030 (US$ Million)
Table 32. Canada Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type - Revenue and Forecast to 2030 (US$ Million)
Table 33. Canada Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type - Revenue and Forecast to 2030 (US$ Million)
Table 34. Mexico Molecular Diagnostic for Infectious Diseases Market, by Type - Revenue and Forecast to 2030 (US$ Million)
Table 35. Mexico Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User - Revenue and Forecast to 2030 (US$ Million)
Table 36. Mexico Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User - Revenue and Forecast to 2030 (US$ Million)
Table 37. Mexico Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application - Revenue and Forecast to 2030 (US$ Million)
Table 38. Mexico Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application - Revenue and Forecast to 2030 (US$ Million)
Table 39. Mexico Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type - Revenue and Forecast to 2030 (US$ Million)
Table 40. Mexico Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing - Revenue and Forecast to 2030 (US$ Million)
Table 41. Mexico Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type - Revenue and Forecast to 2030 (US$ Million)
Table 42. Mexico Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing - Revenue and Forecast to 2030 (US$ Million)
Table 43. Mexico Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type - Revenue and Forecast to 2030 (US$ Million)
Table 44. Mexico Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type - Revenue and Forecast to 2030 (US$ Million)
Table 45. Organic Developments Done By Companies
Table 46. Inorganic Developments Done By Companies
Table 47. Glossary of Terms, Molecular Diagnostic for Infectious Diseases Market

List Of Figures

Figure 1. North America Molecular Diagnostic for Infectious Diseases Market Segmentation, By Country
Figure 2. North America Molecular Diagnostic for Infectious Diseases Market - Key Industry Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. North America Molecular Diagnostic for Infectious Diseases Market Revenue (US$ Mn), 2022 - 2030
Figure 5. North America Molecular Diagnostic for Infectious Diseases Market Revenue Share, by Type, 2022 & 2030 (%)
Figure 6. Point-of-Testing: North America Molecular Diagnostic for Infectious Diseases Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Laboratory Testing: North America Molecular Diagnostic for Infectious Diseases Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. North America Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing and Laboratory Testing by End User, 2022 & 2030 (%)
Figure 9. Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Application, 2022 & 2030 (%)
Figure 10. North America Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Disease Type, 2022 & 2030 (%)
Figure 11. North America Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Infection Type, 2022 & 2030 (%)
Figure 12. North America: Molecular Diagnostic for Infectious Diseases Market, by Key Country - Revenue (2022) (US$ Million)
Figure 13. North America Molecular Diagnostic for Infectious Diseases Market, By Key Countries, 2022 and 2030 (%)
Figure 14. US Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
Figure 15. Canada Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
Figure 16. Mexico Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
Figure 17. Growth Strategies Done by the Companies in the Market, (%)